Compare FFBC & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFBC | VKTX |
|---|---|---|
| Founded | 1863 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.3B |
| IPO Year | 2004 | 2014 |
| Metric | FFBC | VKTX |
|---|---|---|
| Price | $34.49 | $38.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $30.71 | ★ $95.86 |
| AVG Volume (30 Days) | 1.0M | ★ 3.0M |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.34% | N/A |
| EPS Growth | ★ 10.83 | N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.67 | N/A |
| Revenue Next Year | $4.58 | N/A |
| P/E Ratio | $47.90 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.09 | $22.96 |
| 52 Week High | $35.00 | $43.15 |
| Indicator | FFBC | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 65.20 | 60.36 |
| Support Level | $29.32 | $29.10 |
| Resistance Level | $35.00 | $39.78 |
| Average True Range (ATR) | 0.71 | 2.72 |
| MACD | 0.01 | 0.39 |
| Stochastic Oscillator | 85.30 | 69.76 |
First Financial Bancorp is a mid-sized, regional bank holding company. It engages in the business of commercial banking and other banking and banking-related activities through its subsidiary. The range of banking services provided to individuals and businesses includes commercial lending, real estate lending, and consumer financing. Real estate loans are loans secured by a mortgage lien on the real property of the borrower, which may either be residential property or commercial property. In addition, it offers deposit products that include interest-bearing and non-interest-bearing accounts, time deposits, and cash management services for commercial customers. A full range of trust and wealth management services is also provided through First Financial's Wealth Management line of business.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.